专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100247606A1 INTRAOCULAR SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND METHODS FOR TREATING OCULAR CONDITIONS 审中-公开
标题翻译：内镜持续释放药物输送系统及治疗眼睛病症的方法
公开(公告)号：US20100247606A1
公开(公告)日：2010-09-30
申请号：US12411250
申请日：2009-03-25
申请人： Michael R. ROBINSON , James A. Burke , Hui Liu , Werhner C. Orilla , Lon T. Spada , Scott Whitcup , Alazar N. Ghebremskel , Patrick M. Hughes , Kun Xu , Marianne M. Do
发明人： Michael R. ROBINSON , James A. Burke , Hui Liu , Werhner C. Orilla , Lon T. Spada , Scott Whitcup , Alazar N. Ghebremskel , Patrick M. Hughes , Kun Xu , Marianne M. Do
IPC分类号： A61F2/00 , A61K31/215 , A61K31/165 , A61K9/14 , A61K31/4025 , A61K31/426 , A61K31/415 , A61K31/42
CPC分类号： A61K31/557 , A61K9/0051 , A61K9/1647 , A61K9/70 , A61K31/00 , A61K31/5575
摘要： Biocompatible, bioerodible sustained release implants and microspheres for intracameral or anterior vitreal placement include an anti-hypertensive agent and a biodegradable polymer effective to treat an ocular hypertensive condition (such as glaucoma) by relapsing therapeutic amount of the anti-hypertensive agent over a period of time between 10 days and 1 year.
摘要翻译：生物相容性，生物可蚀性缓释植入物和用于乳房内或玻璃体前置放置的微球包括抗高血压剂和可生物降解的聚合物，其通过在一段时间内复发治疗量的抗高血压药物而有效治疗眼高血压病症（如青光眼）时间在10天到1年之间。

2. 发明申请

US20070224278A1 LOW IMMUNOGENICITY CORTICOSTEROID COMPOSITIONS 审中-公开
标题翻译：低免疫球蛋白组合物
公开(公告)号：US20070224278A1
公开(公告)日：2007-09-27
申请号：US11741366
申请日：2007-04-27
申请人： Robert Lyons , Michael Robinson , James Chang , Sam Lam , John Trogden , Scott Whitcup
发明人： Robert Lyons , Michael Robinson , James Chang , Sam Lam , John Trogden , Scott Whitcup
IPC分类号： A61K9/14 , A61K31/56
CPC分类号： A61K9/0019 , A61K9/0048 , A61K31/56 , A61K31/573 , A61K31/58 , A61K31/715 , A61K47/02 , A61K47/34 , A61K47/36 , A61K47/40
摘要： Triamcinolone compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes or into a joint are provided. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps t a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.
摘要翻译：提供了曲安奈德组合物，以及使用这种组合物的方法，其可用于注射到人眼玻璃体或关节中。这样的组合物可以包括以治疗有效量存在的曲安奈德颗粒，粘度诱导组分和水性载体组分。组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。在优选的实施方案中，粘度在约80,000cps至约300,000cps的范围内。在最优选的实施方案中，在25℃下，粘度为约140,000cps至约280,000cps，剪切速率为0.1 /秒。组合物有利地将曲安奈德颗粒悬浮较长时间。

3. 发明申请

US20060106112A1 Treating neurological disorders using selective antagonists of persistent sodium current 有权
标题翻译：使用持续钠电流的选择性拮抗剂治疗神经障碍
公开(公告)号：US20060106112A1
公开(公告)日：2006-05-18
申请号：US11326036
申请日：2006-01-05
申请人： George Ehring , Joseph Adorante , Larry Wheeler , Thomas Malone , Scott Whitcup
发明人： George Ehring , Joseph Adorante , Larry Wheeler , Thomas Malone , Scott Whitcup
IPC分类号： A61K31/13
CPC分类号： A61K31/381 , A61K31/00 , A61K31/136 , A61K31/235 , A61K31/4439
摘要： The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.
摘要翻译：本发明提供了通过向哺乳动物施用有效量的相对于瞬时钠电流具有至少20倍的持续钠电流选择性的选择性持续性钠通道拮抗剂来治疗哺乳动物神经系统疾病的方法。

4. 发明申请

US20050101582A1 Compositions and methods for treating a posterior segment of an eye 审中-公开
标题翻译：用于治疗眼后段的组合物和方法
公开(公告)号：US20050101582A1
公开(公告)日：2005-05-12
申请号：US10966764
申请日：2004-10-14
申请人： Robert Lyons , James Chang , John Trogden , Scott Whitcup
发明人： Robert Lyons , James Chang , John Trogden , Scott Whitcup
IPC分类号： A61K9/00 , A61K31/573 , A61K47/36
CPC分类号： A61K31/58 , A61K9/0048 , A61K31/573 , A61K47/36
摘要： Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.
摘要翻译：提供了组合物和使用这种组合物的方法，其可用于注射到人或动物眼睛的后段中。这样的组合物包括以治疗有效量存在的含皮质类固醇成分的颗粒，粘度诱导组分和水性载体组分。组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。在优选的实施方案中，粘度在约140,000cps至约300,000cps的范围内。组合物有利地将颗粒悬浮长时间。

5. 发明申请

US20060233859A1 Methods for treating retinopathy with extended therapeutic effect 审中-公开
公开(公告)号：US20060233859A1
公开(公告)日：2006-10-19
申请号：US11292544
申请日：2005-12-02
申请人： Scott Whitcup , David Weber
发明人： Scott Whitcup , David Weber
IPC分类号： A61K31/573 , A61F2/00
CPC分类号： A61K9/0051 , A61F9/0017 , A61K9/0024 , A61K9/1647 , A61K31/165 , A61K31/56 , A61K31/57 , A61K39/3955 , A61K47/34 , C07K16/18 , C07K16/22
摘要： Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.

6. 发明申请

US20060009498A1 Ophthalmic compositions and methods for treating ophthalmic conditions 审中-公开
标题翻译：用于治疗眼科疾病的眼用组合物和方法
公开(公告)号：US20060009498A1
公开(公告)日：2006-01-12
申请号：US11180752
申请日：2005-07-11
申请人： Scott Whitcup
发明人： Scott Whitcup
IPC分类号： A61K31/44
CPC分类号： A61K9/0024 , A61K9/0048 , A61K9/0051 , A61K31/44 , A61K31/56 , A61K31/57 , A61K31/573 , A61K31/575 , A61K31/58 , A61K45/06 , A61K47/34 , A61K47/38 , Y10S514/912
摘要： Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component. The composition is in a fluid form before placement in the interior of an eye, and becomes less fluid after the composition is placed in the eye to form an extended or delayed release drug delivery element or system. The drug delivery element is formed by the dissipation of the solvent from the composition when the composition is placed in the interior of an eye. One example of a composition includes triamcinolone acetonide as a therapeutic agent. A method of treating an ophthalmic condition, or otherwise improving or enhancing vision of a patient, comprises placing the fluid composition in the interior of the eye. The method may be practiced by injecting the fluid composition into the interior of the eye.
摘要翻译：提供了组合物和使用这种组合物的方法，其用于将人体或动物眼睛的内部放置，例如注射。这样的组合物包括治疗组分，例如一种或多种皮质类固醇，生物相容性聚合物组分和溶剂组分。组合物在放置在眼睛内部之前是流体形式，并且在将组合物置于眼睛中以形成延长或延迟释放的药物递送元件或系统后变得较少的流体。当组合物放置在眼睛的内部时，通过从组合物中消散溶剂形成药物递送元件。组合物的一个实例包括曲安奈德作为治疗剂。治疗眼睛病症或以其他方式改善或增强患者视力的方法包括将流体组合物置于眼睛的内部。该方法可以通过将流体组合物注入眼睛的内部来实施。

7. 发明申请

US20050054695A1 Treating neurological disorders using selective antagonists of persistent sodium current 有权
标题翻译：使用持续钠电流的选择性拮抗剂治疗神经障碍
公开(公告)号：US20050054695A1
公开(公告)日：2005-03-10
申请号：US10928949
申请日：2004-08-27
申请人： George Ehring , Joseph Adorante , Larry Wheeler , Thomas Malone , Scott Whitcup
发明人： George Ehring , Joseph Adorante , Larry Wheeler , Thomas Malone , Scott Whitcup
IPC分类号： A61K31/00 , A61K31/136 , A61K31/235 , A61K31/381 , A61K31/4439 , A61K31/433 , A61K31/13
CPC分类号： A61K31/381 , A61K31/00 , A61K31/136 , A61K31/235 , A61K31/4439
摘要： The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.
摘要翻译：本发明提供了通过向哺乳动物施用有效量的相对于瞬时钠电流具有至少20倍的持续钠电流选择性的选择性持续性钠通道拮抗剂来治疗哺乳动物神经系统疾病的方法。

8. 发明授权

US07977335B2 Methods of preventing and reducing the severity of stress-associated conditions 有权
标题翻译：预防和减轻压力相关病症严重程度的方法
公开(公告)号：US07977335B2
公开(公告)日：2011-07-12
申请号：US12114727
申请日：2008-05-02
申请人： Daniel W. Gil , Scott Whitcup , Mitchell F. Brin , John E. Donello
发明人： Daniel W. Gil , Scott Whitcup , Mitchell F. Brin , John E. Donello
IPC分类号： A61K31/198
CPC分类号： A61K31/498
摘要： The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, stereoisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatological conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders.
摘要翻译：本发明提供了通过向受试者全身施用有效量的溴莫尼定或其药学上可接受的盐，酯，酰胺，立体异构体或外消旋混合物来提供预防或减轻受试者的应激相关状况的严重性的方法。可以根据本发明的方法治疗的应激相关病症包括但不限于消化不良，与心肌缺血相关的心动过速以外的心动过速，惊恐发作，非炎性皮肤病学条件，肌肉收缩障碍，感觉超敏反应与偏头痛和行为障碍相关。

9. 发明申请

US20070112032A1 Prevention and/or reduction of photoreceptor degeneration with retinoids 审中-公开
标题翻译：用类维生素A预防和/或减少感光器变性
公开(公告)号：US20070112032A1
公开(公告)日：2007-05-17
申请号：US10580879
申请日：2004-11-30
申请人： Scott Whitcup , Roshantha Chandraratna , Ronald Lai
发明人： Scott Whitcup , Roshantha Chandraratna , Ronald Lai
IPC分类号： A61K31/4436
CPC分类号： A61K9/0048 , A61K31/00 , A61K31/203 , A61K31/4436 , Y02A50/401
摘要： The present invention provides a method for reducing and/or preventing degeneration of photoreceptors in the eye of a human caused by radiation in the visible range which comprises administering to said mammal a retinoid compound having RARβ and/or RARδ-selective agonist activity.
摘要翻译：本发明提供了一种用于减少和/或预防由可见光范围内的辐射引起的人眼中光感受器变性的方法，该方法包括向所述哺乳动物施用具有RARβ和/或 RAR三角选择性激动剂活性。

10. 发明申请

US20070059336A1 Anti-angiogenic sustained release intraocular implants and related methods 审中-公开
标题翻译：抗血管生成持续释放眼内植入物及相关方法
公开(公告)号：US20070059336A1
公开(公告)日：2007-03-15
申请号：US11364687
申请日：2006-02-27
申请人： Patrick Hughes , Thomas Malone , Gerald De Vries , Jeffrey Edelman , Wendy Blanda , Lon Spada , Peter Baciu , Scott Whitcup
发明人： Patrick Hughes , Thomas Malone , Gerald De Vries , Jeffrey Edelman , Wendy Blanda , Lon Spada , Peter Baciu , Scott Whitcup
IPC分类号： A61K38/18 , A61K39/395
CPC分类号： A61K48/0041 , A61K9/0051
摘要： Biocompatible intraocular drug delivery systems include a anti-angiogenic therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent may be selected from the group consisting of anti-angiogenesis peptides, hormones and nucleic acid agents. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.
摘要翻译：生物相容性眼内药物递送系统包括抗血管生成治疗剂和植入物，微粒，多种植入物或微粒形式的聚合物组分及其组合。治疗剂以生物活性形式释放，例如，当释放到患者的眼睛中时，治疗剂可以保持其三维结构，或者治疗剂可以具有改变的三维结构，但保持其治疗活性。治疗剂可以选自抗血管生成肽，激素和核酸试剂。植入物可以置于眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变等。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式